Capricorn Fund Managers Ltd Invests in Taysha Gene Therapies

New $1.65 million stake in biotech company developing gene therapies for rare CNS disorders

Apr. 6, 2026 at 8:42am

Got story updates? Submit your updates here. ›

Capricorn Fund Managers Ltd, a UK-based investment firm, has purchased a new stake of 300,000 shares in Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. The $1.65 million investment represents a 0.11% ownership stake in Taysha Gene Therapies.

Why it matters

Taysha Gene Therapies is a promising biotech startup working on innovative gene therapy treatments for rare and life-threatening pediatric CNS disorders. This new investment from Capricorn Fund Managers, a respected institutional investor, signals confidence in the company's pipeline and future growth potential.

The details

Capricorn Fund Managers purchased the 300,000 shares of Taysha Gene Therapies during the fourth quarter of 2025, according to the firm's recent 13F filing with the SEC. The investment gives Capricorn a 0.11% ownership stake in the Dallas-based biotech company.

  • Capricorn Fund Managers purchased the Taysha Gene Therapies shares in Q4 2025.
  • Taysha Gene Therapies was founded in 2019 and completed its IPO in May 2021.

The players

Capricorn Fund Managers Ltd

A UK-based investment management firm that has purchased a new stake in Taysha Gene Therapies.

Taysha Gene Therapies, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Got photos? Submit your photos here. ›

The takeaway

This investment from Capricorn Fund Managers underscores the growing investor interest and confidence in Taysha Gene Therapies' potential to develop transformative gene therapies for rare neurological diseases.